Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
NCT00053352
Completed
This phase III trial is studying surgery followed by combination chemotherapy to see how well it works in treating children with germ cell tumors that are not located in the head. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, and giving them after surgery, may kill any remaining tumor cells following surgery. It is not yet known whether combination chemotherapy is effective in decreasing the recurrence o... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/09/2021
Locations: University of Alabama at Birmingham, Birmingham, Alabama +125 locations
Conditions: Childhood Embryonal Tumor, Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Childhood Teratoma, Ovarian Embryonal Carcinoma, Ovarian Yolk Sac Tumor, Stage II Malignant Testicular Germ Cell Tumor, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Ovarian Germ Cell Tumor, Stage III Malignant Testicular Germ Cell Tumor, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIC Ovarian Germ Cell Tumor, Testicular Choriocarcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma
Register for Updates
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
NCT02715531
Completed
This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab in combination with bevacizumab, bevacizumab + oxaliplatin, leucovorin and 5-fluorouracil (5-FU) (FOLFOX), vanucizumab, nab-paclitaxel + gemcitabine, FOLFOX, or 5-FU + cisplatin, in participants with solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2021
Locations: Stanford Cancer Institute; Hematology, Palo Alto, California +29 locations
Conditions: Solid Tumor
Register for Updates
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
NCT00700336
Completed
The phase I part of the study is a dose-finding study of escalating doses of CBP501 combined with full-dose cisplatin and pemetrexed in patients with histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or would otherwise be eligible for cisplatin and pemetrexed as first-line therapy. The maximum tolerated dose (MTD) will be determined based on DLTs occurring during the first tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2021
Locations: Mayo Clinic, Scottsdale, Arizona +11 locations
Conditions: Malignant Pleural Mesothelioma, Solid Tumors
Register for Updates
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
NCT02585973
Completed
This open label, single-arm, Phase 1b study is designed to identify the maximum tolerated dose (MTD) using a traditional 3+3 dose escalation design of the WEE-1 inhibitor AZD1775 when added to standard of care chemotherapy (cisplatin) and radiation for the treatment of locally advanced squamous cell cancer of the head and neck (HNSCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2021
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Carcinoma, Squamous Cell of Head and Neck
Register for Updates
Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer
NCT02550327
Completed
The objective of this study is to improve survival by the addition of anakinra to the chemotherapy combination of nab-paclitaxel, gemcitabine, and cisplatin in patients with resectable or potentially resectable pancreatic adenocarcinoma (PDAC). The primary endpoint of the study is to determine whether the combination of abraxane, gemcitabine, cisplatin, and anakinra will improve disease-free survival (DFS) and to determine the number of patients who meet or surpass 11.5 months of DFS. The secon... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2021
Locations: Baylor Charles A. Sammons Cancer Center, Dallas, Texas
Conditions: Pancreatic Adenocarcinoma
Register for Updates
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
NCT02128230
Terminated
The purpose of this study is to improve the clinical outcomes of research subjects with high-risk multiple myeloma in the context of the immediately preceding Total therapy 5 trial 2008-02 and Total therapy 3 trials 2003-33 and 2006-66.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/28/2021
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
NCT02092298
Completed
The goal of this clinical research study is to learn if hyperthermic intraperitoneal chemotherapy (HIPEC) will help to control the disease in patients with Stage 4 stomach or gastroesophageal cancer. The safety of this treatment will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2021
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Gastrointestinal Cancer
Register for Updates
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
NCT02768558
Terminated
Patients with Stage III unresectable non-small cell lung cancer will receive thoracic radiation, cisplatin and etoposide followed by nivolumab or placebo given every 2 weeks for a year.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2021
Locations: UC San Diego Moores Cancer Center, La Jolla, California +15 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
NCT00580333
Completed
The purpose of this study is to find out what effect taking cisplatin in combination with bevacizumab before surgery and then standard chemotherapy plus bevacizumab after surgery will have on participants with Estrogen Receptor (ER) negative, Progesterone Receptor (PR) negative and Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer. Cisplatin is used to destroy cancer cells in many types of cancers, and has shown to be effective and have manageable side effects. Bevacizumab i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2021
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Breast Cancer
Register for Updates
Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer
NCT01016561
Terminated
Rationale: Computer systems that allow doctors to create a 3 dimensional (3-D) picture of the tumor may help in planning radiation therapy and may result in more tumor cells being killed. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs, such as cisplatin, may make tumor cells more sensitive to radiation therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/03/2021
Locations: Abramson Cancer Center of the Unviersity of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cervical Cancer
Register for Updates
Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer
NCT01459614
Completed
Primary Objectives To assess the efficacy of the combination of gemcitabine, taxotere, and xeloda (GTX) with cisplatin in subjects with metastatic pancreatic cancer based on the progression-free survival (PFS) rate at 6 month. Secondary Objectives * To assess safety and characterize toxicities of the combination of GTX with cisplatin in subjects with metastatic pancreatic cancer. * To estimate disease control rate (DCR), PFS, and overall survival (OS). * To estimate a PFS rate of an expansion... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/29/2021
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Pancreatic Cancer
Register for Updates
Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
NCT00582205
Terminated
The purpose of this study is to evaluate giving chemotherapy drugs directly into the abdomen (belly) along with intravenous administration.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
04/28/2021
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer
Register for Updates